Shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) have been assigned a consensus rating of “Buy” from the ...

Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

KBC Group NV purchased a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 3,020 shares of the company’s ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Ted Myles, COO & CFO at Scholar Rock, will remain with the Company through mid-March, and then serve as a Senior Advisor for six months, during the leadership transition. “I am delighted to have ...

CAMBRIDGE, MA—Ho Junlin, General Counsel of Scholar Rock Holding Corp (NASDAQ:SRRK), recently sold 9,039 shares of the company's common stock. The shares were sold at an average price of $44. ...

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months, ...

Lilly is testing bimagrumab alone and in combination with Novo's Wegovy -- a mid-stage trial begun before the acquisition -- ...